A Phase 2 interventional study of JNJ-64565111 Dose Level 1 and JNJ-64565111 Dose Level 2 in Obesity, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Obesity by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Obesity · Johnson & Johnson.
Among the 35 studies in Obesity by Johnson & Johnson, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 2, and was the 32nd registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →None of the 35 studies in Obesity by Johnson & Johnson is open now. The open studies under Obesity, anywhere →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 474 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 113 across the 31 interventional studies, 65 across the 4 observational. Of the 35 that completed or were terminated, 13 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Obesity by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
Drug: JNJ-64565111 Dose Level 1
Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
Drug: JNJ-64565111 Dose Level 2
Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
Drug: JNJ-64565111 Dose Level 3
Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
Drug: Placebo
Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Drug: Liraglutide
Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Also known as: Saxenda
Participants will receive matching placebo SC once-weekly until Week 26.
Percent Change From Baseline in Body Weight at Week 26
Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported.
Time frame: Baseline, Week 26
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE was defined as an AE with an onset after the initiation study drug and before the last study drug date of the double-blind (26-week) treatment phase for plus 28 days for liraglutide participants, and plus 35 days for JNJ-64565111 and placebo participants.
Time frame: Up to Week 30
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26
Number of participants with \>= 5% body weight loss from baseline to Week 26 were reported.
Time frame: Week 26
Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26
Number of participants with \>= 10 % body weight loss from baseline to Week 26 were reported.
Time frame: Week 26
Change From Baseline in Body Weight at Week 26
Change from baseline in body weight at Week 26 was reported.
Time frame: Baseline, Week 26
| Milestone | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Started | 60 | 59 | 118 | 118 | 119 |
| Completed | 57 | 59 | 104 | 109 | 115 |
| Not completed | 3 | 0 | 14 | 9 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 8 | 5 | 2 |
| Withdrew: Withdrawal by subject | 3 | 0 | 6 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported.
| Percent Change | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 26 | -1.76 ± 0.73 | -8.51 ± 0.76 | -9.83 ± 0.56 | -11.80 ± 0.58 | -7.54 ± 0.54 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE was defined as an AE with an onset after the initiation study drug and before the last study drug date of the double-blind (26-week) treatment phase for plus 28 days for liraglutide participants, and plus 35 days for JNJ-64565111 and placebo participants.
| Participants | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 43 | 53 | 110 | 110 | 96 |
Number of participants with \>= 5% body weight loss from baseline to Week 26 were reported.
| Participants | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26 | 8 | 34 | 70 | 62 | 56 |
Number of participants with \>= 10 % body weight loss from baseline to Week 26 were reported.
| Participants | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26 | 2 | 23 | 43 | 46 | 27 |
Change from baseline in body weight at Week 26 was reported.
| kg | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | -2.05 ± 0.827 | -9.58 ± 0.861 | -11.07 ± 0.633 | -13.23 ± 0.656 | -8.32 ± 0.610 |
Collected over Up to 30 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind: Placebo | 0/60 (0%) | 4/60 (6.7%) | 33/60 (55%) |
| Double Blind: JNJ-64565111 5.0 mg | 0/59 (0%) | 3/59 (5.1%) | 43/59 (72.9%) |
| Double Blind: JNJ-64565111 7.4 mg | 0/118 (0%) | 2/118 (1.7%) | 106/118 (89.8%) |
| Double Blind: JNJ-64565111 10.0 mg | 0/118 (0%) | 4/118 (3.4%) | 104/118 (88.1%) |
| Open Label: Liraglutide 3.0 mg | 1/119 (0.8%) | 4/119 (3.4%) | 81/119 (68.1%) |
| Event | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| IleusGastrointestinal disorders | 0/60 | 1/59 | 0/118 | 0/118 | 0/119 |
| VomitingGastrointestinal disorders | 0/60 | 0/59 | 1/118 | 2/118 | 0/119 |
| Biliary ColicHepatobiliary disorders | 0/60 | 1/59 | 0/118 | 0/118 | 1/119 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/60 | 1/59 | 0/118 | 0/118 | 0/119 |
| Umbilical HerniaGastrointestinal disorders | 1/60 | 0/59 | 0/118 | 0/118 | 0/119 |
| ObesityMetabolism and nutrition disorders | 1/60 | 0/59 | 0/118 | 0/118 | 0/119 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/60 | 0/59 | 0/118 | 0/118 | 0/119 |
| MenorrhagiaReproductive system and breast disorders | 1/60 | 0/59 | 0/118 | 0/118 | 0/119 |
| Stress CardiomyopathyCardiac disorders | 0/60 | 0/59 | 1/118 | 0/118 | 0/119 |
| PneumoniaInfections and infestations | 0/60 | 0/59 | 0/118 | 1/118 | 0/119 |
| Event | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/60 | 30/59 | 80/118 | 79/118 | 48/119 |
| VomitingGastrointestinal disorders | 0/60 | 12/59 | 47/118 | 64/118 | 20/119 |
| DiarrhoeaGastrointestinal disorders | 3/60 | 8/59 | 24/118 | 23/118 | 27/119 |
| ConstipationGastrointestinal disorders | 3/60 | 7/59 | 20/118 | 21/118 | 20/119 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/60 | 10/59 | 16/118 | 20/118 | 10/119 |
| HeadacheNervous system disorders | 6/60 | 7/59 | 20/118 | 8/118 | 9/119 |
| DyspepsiaGastrointestinal disorders | 2/60 | 5/59 | 18/118 | 13/118 | 9/119 |
| NasopharyngitisInfections and infestations | 9/60 | 5/59 | 11/118 | 6/118 | 10/119 |
| FatigueGeneral disorders | 2/60 | 7/59 | 15/118 | 17/118 | 5/119 |
| EructationGastrointestinal disorders | 0/60 | 4/59 | 14/118 | 16/118 | 5/119 |
| Age, Continuous(years) | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 46.9 ± 11.84 | 47.3 ± 11.18 | 46.2 ± 11.68 | 46.2 ± 12.16 | 45.6 ± 11.71 | 46.3 ± 11.73 |
| Sex: Female, Male(Participants) | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg | Total |
|---|---|---|---|---|---|---|
| Female | 48 | 47 | 86 | 86 | 89 | 356 |
| Male | 12 | 12 | 32 | 32 | 30 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 9 | 11 | 14 | 42 |
| Not Hispanic or Latino | 57 | 54 | 108 | 107 | 105 | 431 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 | 1 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 3 | 1 | 4 |
| Black or African American | 8 | 3 | 8 | 8 | 7 | 34 |
| White | 51 | 56 | 106 | 103 | 105 | 421 |
| More than one race | 0 | 0 | 2 | 2 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 1 | 3 |
| Region of Enrollment(Participants) | Double Blind: Placebo | Double Blind: JNJ-64565111 5.0 mg | Double Blind: JNJ-64565111 7.4 mg | Double Blind: JNJ-64565111 10.0 mg | Open Label: Liraglutide 3.0 mg | Total |
|---|---|---|---|---|---|---|
| BELGIUM | 7 | 5 | 15 | 13 | 18 | 58 |
| CANADA | 9 | 8 | 12 | 17 | 16 | 62 |
| POLAND | 8 | 6 | 14 | 18 | 15 | 61 |
| SWEDEN | 12 | 14 | 22 | 19 | 14 | 81 |
| UNITED KINGDOM | 5 | 8 | 17 | 11 | 17 | 58 |
| UNITED STATES | 19 | 18 | 38 | 40 | 39 | 154 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Mar 2019, 11 months.
Results were first posted in Feb 2020, 10 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Janssen Research & Development, LLC →